DarPharma, founded in October 2000, has licensed a large intellectual property portfolio of dopamine D1 agonists and other drug candidates from the University of North Carolina at Chapel Hill and Purdue University. It aims to bring to market the first dopamine D1 receptor full agonists as therapeutics for the management of multiple CNS conditions, including first-ever drug treatments for late-stage Parkinson''s disease and the cognitive deficits and negative symptoms associated with schizophrenia. DarPharma''s lead compound, DAR-0100, is in an ongoing Phase I/IIa clinical trial in late-stage Parkinson''s disease patients and is soon to enter Phase II trials for psychiatric indications. Currently, DarPharma has active clinical and preclinical programs for six indications, including Parkinson''s disease and schizophrenia.
| Website | http://darpharma.com/ |
| Revenue | $4 million |
| Employees | 1 (1 on RocketReach) |
| Founded | 2017 |
| Phone | +84 912 278 195 |
| Fax | (919) 403-4369 |
| Technologies |
JavaScript
,
HTML
,
PHP
+17 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Biopharma, Healthcare, Drug Manufacturing & Research, Health Care, Science and Engineering, Pharmaceutical, Therapeutics |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Lilly India +45 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular DarPharma , Inc. employee's phone or email?
DarPharma , Inc. Questions
The DarPharma , Inc. annual revenue was $4 million in 2026.
1 people are employed at DarPharma , Inc..
The NAICS codes for DarPharma , Inc. are [32, 325, 3254, 32541].
The SIC codes for DarPharma , Inc. are [283, 28].
Top DarPharma , Inc. Employees
